|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
SCIDIR_on1313607726 |
| 003 |
OCoLC |
| 005 |
20231120010643.0 |
| 006 |
m o d |
| 007 |
cr un|---aucuu |
| 008 |
220503s2022 enk o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e rda
|e pn
|c YDX
|d OPELS
|d EBLCP
|d GZM
|d OCLCF
|d OCLCQ
|d N$T
|d OCLCO
|
| 019 |
|
|
|a 1313903473
|
| 020 |
|
|
|a 9780323961370
|q (electronic bk.)
|
| 020 |
|
|
|a 0323961371
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323961363
|
| 020 |
|
|
|z 0323961363
|
| 035 |
|
|
|a (OCoLC)1313607726
|z (OCoLC)1313903473
|
| 050 |
|
4 |
|a RC280.B8
|
| 082 |
0 |
4 |
|a 616.9944906
|2 23
|
| 100 |
1 |
|
|a Mir, Manzoor Ahmad.
|
| 245 |
1 |
0 |
|a Combinational therapy in triple negative breast cancer /
|c Manzoor Mir.
|
| 264 |
|
1 |
|a London, United Kingdom :
|b Academic Press,
|c 2022.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Front cover -- Half title -- Copyright -- Contents -- Contributors -- About the author -- Foreword -- Preface -- Acknowledgment -- Chapter 1 -- Triple-negative breast cancer -- an aggressive subtype of breast cancer -- Introduction -- Triple-negative breast cancer (TNBC) -- TNBC histological classification -- TNBC molecular classification -- BL-1 and BL-2 -- M subtype -- MSL subtype -- IM subtype -- LAR subtype -- TNBC and BRCA -- Triple-negative breast cancer risk factors and epidemiology -- Current diagnostic options for triple-negative breast cancer -- Mammography -- Ultrasound
|
| 505 |
8 |
|
|a Magnetic resonance imaging (MRI) -- Future diagnostic options for TNBC -- Blood-based liquid biopsy -- Circulating tumor nucleic acids (ctNAs) -- Exosomes -- Immuno-positron emission tomography (PET) -- Nanobiosensor -- nCounter breast cancer 360 panel -- Digital polymerase chain reaction (dPCR) -- Triple-negative breast cancer's prognostic implications -- Somatic genomic mutations in TNBC -- Epigenetic modifications in TNBC -- Methylation of DNA in triple-negative breast cancer -- Relation between DNA methylation and TNBC progression -- Role of long noncoding RNAs in TNBC
|
| 505 |
8 |
|
|a Role of MicroRNA in TNBC -- Role of histone modifications in TNBC -- Summary -- References -- Chapter 2 -- Novel biomarkers in triple-negative breast cancer -- role and perspective -- Introduction -- Triple-negative breast cancer: Genetic markers -- TP53 -- BRCA1/2 -- PI3K pathway -- Androgen receptor -- BCL2 gene -- Cyclin-dependent kinases -- Triple-negative breast cancer: Novel biomarkers -- EGFR -- VEGF -- C-kit and basal cytokeratins -- TOP-2A -- Ki67 -- PARP -- Heat shock protein 90 -- Cox-2 -- Epigenetic modifications in TNBC as novel biomarkers -- Tissue miRNAs as biomarkers in TNBC
|
| 650 |
|
0 |
|a Breast
|x Cancer
|x Treatment.
|
| 650 |
|
6 |
|a Sein
|0 (CaQQLa)201-0071080
|x Cancer
|0 (CaQQLa)201-0071080
|x Traitement.
|0 (CaQQLa)201-0377521
|
| 650 |
|
7 |
|a Breast
|x Cancer
|x Treatment
|2 fast
|0 (OCoLC)fst00838313
|
| 776 |
0 |
8 |
|i Print version:
|z 0323961363
|z 9780323961363
|w (OCoLC)1273915344
|
| 776 |
0 |
8 |
|i Print version:
|a MIR, MANZOOR AHMAD.
|t COMBINATIONAL THERAPY IN TRIPLE NEGATIVE BREAST CANCER.
|d [S.l.] : ELSEVIER ACADEMIC PRESS, 2022
|z 0323961363
|w (OCoLC)1273915344
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780323961363
|z Texto completo
|
